ASAHI INTECC CO.,LTD. (7747) Stock Price

Asahi Intecc is a research and development-focused manufacturer that develops, manufactures, and sells medical devices and industrial equipment products. The company specializes in minimally invasive treatment products for endovascular therapy, particularly guidewires and catheters.

The company serves hospitals and medical institutions as its primary customers. In Japan, it primarily uses direct sales, while overseas it mainly operates through sales distributors. In major markets such as the United States, France, Germany, and Italy, the company also conducts direct sales through local subsidiaries. Medical products account for the majority of revenue, while the supply of industrial materials also contributes to sales.

The company's business is structured around two main pillars: the Medical Business and the Device Business. The Medical Business handles products in the circulatory, peripheral, abdominal, and cerebrovascular fields, while the Device Business supplies materials for medical and industrial manufacturers. The company differentiates itself through integrated production utilizing core technologies including wire drawing, wire forming, coating, and torque control, with a system capable of handling everything from raw materials to finished products.

The company has established a long-term vision to become a global niche leader, with minimally invasive treatment as its core focus. Specifically, it targets consolidated net sales of 300 billion yen and an operating profit margin of 30% by June 2035, with an intermediate milestone of 180 billion yen in consolidated net sales and a 28% operating profit margin by June 2030 under its new medium-term plan "Building the Future 2030." Additionally, the company aims to achieve return on equity (ROE) and return on invested capital (ROIC) both exceeding 16% by 2030, thereby improving profitability and capital efficiency.

In priority investment areas, the company strengthens its cardiovascular business while expanding into non-cardiovascular segments including peripheral vascular, cerebrovascular, abdominal, and gastrointestinal fields. While maintaining the number-one position in core products such as PCI guide wires and penetrating catheters, the company focuses on developing high-value-added devices for challenging treatment areas such as calcified lesions and CTO (chronic total occlusion). Competitive differentiation stems from integrated production technology spanning from raw materials through finished products—including wire drawing, wire forming, and surface treatment—and a direct sales structure that collaborates closely with physicians.

For new market development and business expansion, the company prioritizes strengthening sales capabilities in the 121 countries and regions where it already supplies products. Domestically, it expands market share and revenue through direct hospital sales. In the United States and major European markets, it strengthens direct sales through local subsidiaries to capture non-cardiovascular market opportunities. In China and emerging markets, the company pursues demand capture through partnerships with local distributors and logistics platforms, while simultaneously expanding production capacity and optimizing facilities—including expansion of the Hanoi factory—to enhance supply-demand responsiveness.

Regarding technological innovation, the company strengthens its globally distributed research and development structure. It has established systems at U.S. and Thai facilities to directly incorporate clinical feedback, while domestically it disperses specialized centers around the Seto R&D Center to balance risk management and advancement. Beyond developing high-value-added treatment devices, the company considers external technology adoption, acquisitions, and partnerships as needed. It pursues sustained competitive advantage through product portfolio expansion, productivity improvement, talent development, digitalization, and sustainability initiatives.